帕比司他加来那度胺Lenalidomide用于套细胞淋巴瘤MCL.pdfVIP

V O L U M E 3 1 N U M B E R 2 9 O C T O B E R 1 0 2 0 1 3 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Phase Ib Study of Panobinostat and Bortezomib in Relapsed or Relapsed and Refractory Multiple Myeloma Jesu´s F. San-Miguel, Paul G. Richardson, Andreas Gu¨nther, Orhan Sezer, David Siegel, Joan Blade´, Richard LeBlanc, Heather Sutherland, Monika Sopala, Kaushal K. Mishra, Song Mu, Priscille M. Bourquelot, María Victoria Mateos, and Kenneth C. Anderson Jesu´s F. San-Miguel and María Victoria A B S T R A C T Mateos, Servicio e Hematologia, Hospi- tal Universitario de Salamanca, Instituto de Investigacio´n Biome´dica de Sala- Purpose manca, Institut de Bilogia Molecular de Despite advancements, prognosis for patients with relapsed/refractory multiple myeloma (MM) is Barcelona (Universidad de Salamanca– poor, and novel therapies are needed. Panobinostat is a potent deacetylase inhibitor that elicits Spanish National Research Council), synergistic effects on MM cells in combination with bortezomib. This phase Ib study sought to Salamanca; Joan Blade´, Hospital Clinic determine the maximum-tolerated dose (MTD) of panobinostat plus bortezomib in patients with de Barcelona, Institut d’Investigacions relapsed or relapsed and refractory MM. Biome`diques August Pi i Sunyer, Barce- lona, Spain; Paul G. Richardson and Patients and Methods Kenneth C. Anderson, Dana-Farber In the dose-escalation phase (n 47), panobinostat was administ